Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion’s strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her r ...